PRISM BioLab is pleased to announce that our President and CEO, Dai Takehara, will speak at the LINK-J symposium “Drug Discovery Frontier 2026.” This symposium will cover cutting-edge topics including the science of sleep and medical approaches, TPD (Targeted Protein Degradation inducers), RI pharmaceuticals, peptide-mimetic compounds, gene editing technology, and iPSC cell therapy. Takehara will...

PRISM BioLab today announced that the abstract titled “Leveraging E7386 phase 1 trials for cardiac safety: gaining concentration-QTc insights to inform early-stage oncology development” is now available. E7386 is a molecule jointly created by PRISM BioLab and Eisai Co., Ltd. The results will be published as an ASCO Online Publication by Eisai at the American...

PRISM BioLab announces that our President and CEO, Dai Takehara, will participate as a speaker at the Radio NIKKEI Japan Tour “Bio IR & Hideaki Sakurai Stock Seminar in Osaka,” to be held on Saturday, June 13, 2026. The seminar details are provided below. We look forward to your participation. For more details, please click...

この度、当社とBoehringer Ingelheim International GmbHとの間で締結している研究及びライセンス契約につきまして、契約期間満了に伴い終了することとなりましたので、お知らせいたします。

PepMetics®技術ライブラリー化合物群の米国における特許査定についてお知らせいたします。

PRISM BioLab announces that Eisai Co., Ltd. will present preclinical research results for E7386, co-created by PRISM BioLab and Eisai, in combination with lenvatinib mesylate, at the American Association for Cancer Research (AACR) Annual Meeting 2026 from April 17 to 22, 2026. The abstract of the study has been disclosed. For more details, please click...

PRISM BioLabとReceptor.AI Inc.は、細胞内タンパク質-タンパク質相互作用（Protein- Protein Interaction、PPI）及び膜タンパク質を標的とした新規低分子医薬品の探索、並 びにAIナビゲート型・物理学ベースの統合創薬プラットフォームを構築する創薬提携契約 を締結したことをお知らせいたします。

PRISM Biolabは、このたび、当社とエーザイ株式会社により共同創出されたE7386について、国内第Ⅰ相臨床試験結果に関する学術論⽂が、ESMO（European Society for Medical Oncology、欧州臨床腫瘍学会）の発⾏するオープンアクセス医学誌である「ESMO OPEN」誌にて公開されましたことをお知らせいたします。

We would like to inform you that PRISM BioLab will relocate our Tokyo office to the address below, effective January 19, 2026. Please note that our main phone number will remain unchanged. Relocation Date: January 19, 2026 New Address: Nihonbashi Life Science Building 2, Room 401 3-11-5 Nihonbashi-Honcho, Chuo-ku Tokyo 103-0023, Japan Phone: +81-466-53-8383 (Main)...

PRISM BioLabとTalus Bioscience, Inc.は、転写因子及びタンパク質／タンパク質間相互作用（PPI）標的に対する新規阻害剤の探索を目的とした共同研究契約を締結したことをお知らせいたします。